We can readily understand why investors are attracted to unprofitable companies. By way of example, Microbot Medical (NASDAQ:MBOT) has seen its share price rise 142% over the last year, delighting ...
Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 434.50% Upside As of ...
Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Microbot Medical ( (MBOT)) just unveiled ...
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), a medical device company with a market capitalization of $159 million, has secured a partnership with a U.S.-based third-party logistics company ...
Harel Gadot, CEO of Microbot Medical Inc. (NASDAQ:MBOT), was recently a guest on Benzinga's All Access. Microbot Medical makes the LIBERTY® Endovascular Robotic System, a single-use, fully disposable ...
MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...
Microbot Medical Inc. MBOT has been granted a new U.S. patent that broadens the potential applications of its LIBERTY Endovascular Robotic System. The patent covers a modular design that allows ...
HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced it has been approved to receive a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback